Vertex Pharmaceuticals Incorporated

NasdaqGS:VRTX Stock Report

Market Cap: US$107.8b

Vertex Pharmaceuticals Future Growth

Future criteria checks 3/6

Vertex Pharmaceuticals is forecast to grow earnings and revenue by 11.2% and 8.6% per annum respectively. EPS is expected to grow by 10.2% per annum. Return on equity is forecast to be 22.8% in 3 years.

Key information

11.2%

Earnings growth rate

10.2%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate8.6%
Future return on equity22.8%
Analyst coverage

Good

Last updated25 Mar 2024

Recent future growth updates

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07
Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Recent updates

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Mar 21

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Mar 15
Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Feb 28

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Feb 22
We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07
Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Jan 22

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Jan 15
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dec 25
Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Nov 13
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Oct 02
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jul 31
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Jul 03
We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued

Apr 30
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Apr 03
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued

Jan 23
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Jan 02
If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?

Oct 24
Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?

Vertex to advance two AAT correctors to potentially treat rare, genetic disease

Oct 11

Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?

Oct 02
Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?

Vertex in licensing agreement with MaxCyte to use platform for gene editing candidate

Sep 28

Vertex Pharmaceuticals: Clinical Data Supports A Favorable Long-Term Growth Outlook

Sep 19

Vertex wins FDA label expansion for cystic fibrosis drug to add younger children

Sep 02

Vertex: CF Monopoly, Looking To Expand

Aug 05

Vertex to run late-stage studies for pain therapy in 4Q 2022

Jul 22

Earnings and Revenue Growth Forecasts

NasdaqGS:VRTX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202612,9085,1015,3295,46024
12/31/202511,7394,4984,6134,86730
12/31/202410,7313,8954,2854,84030
12/31/20239,8693,6203,2793,537N/A
9/30/20239,6543,4704,2054,381N/A
6/30/20239,5053,3653,8794,068N/A
3/31/20239,2083,2603,8904,074N/A
12/31/20228,9313,3223,9254,130N/A
9/30/20228,7013,2733,8144,047N/A
6/30/20228,3503,1953,7874,018N/A
3/31/20227,9482,4512,4512,679N/A
12/31/20217,5742,3422,4092,644N/A
9/30/20217,1302,1761,9192,140N/A
6/30/20216,6841,9921,7772,121N/A
3/31/20216,4152,7623,0483,359N/A
12/31/20206,2062,7122,9943,254N/A
9/30/20205,9912,6912,9793,208N/A
6/30/20205,4032,0812,5572,635N/A
3/31/20204,8191,5111,9832,060N/A
12/31/20194,1631,1771,4941,569N/A
9/30/20193,6202,1441,3631,438N/A
6/30/20193,4542,2151,4131,484N/A
3/31/20193,2652,1551,2581,342N/A
12/31/20183,0482,0961,1751,270N/A
9/30/20182,8296471,0601,183N/A
6/30/20182,623415682972N/A
3/31/20182,415226554832N/A
12/31/20172,489263586845N/A
9/30/20172,296196N/A762N/A
6/30/20172,131259N/A658N/A
3/31/20172,019177N/A517N/A
12/31/20161,702-112N/A236N/A
9/30/20161,661-219N/A121N/A
6/30/20161,557-275N/A-7N/A
3/31/20161,292-399N/A-158N/A
12/31/20151,032-556N/A-365N/A
9/30/2015759-659N/A-576N/A
6/30/2015628-734N/A-602N/A
3/31/2015600-704N/A-620N/A
12/31/2014580-738N/A-573N/A
9/30/2014787-582N/A-362N/A
6/30/2014830-530N/A-289N/A
3/31/20141,002-428N/A-162N/A
12/31/20131,212-504N/A-61N/A
9/30/20131,195-559N/A-40N/A
6/30/20131,309-499N/A80N/A
3/31/20131,417-506N/A199N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VRTX's forecast earnings growth (11.2% per year) is above the savings rate (2.3%).

Earnings vs Market: VRTX's earnings (11.2% per year) are forecast to grow slower than the US market (13.4% per year).

High Growth Earnings: VRTX's earnings are forecast to grow, but not significantly.

Revenue vs Market: VRTX's revenue (8.6% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: VRTX's revenue (8.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VRTX's Return on Equity is forecast to be high in 3 years time (22.8%)


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.